Lucid Diagnostics Could Be 'High In The Queue' For Medicare Coverage Decision, Analyst Says
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst maintains Buy rating and $2.50 PT.
Read original at benzingaStocks · News reference
Ascendiant Capital Maintains Buy on Lucid Diagnostics, Raises Price Target to $9.5
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and raises the price target from $9.25 to $9.5.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 27, 2026, 11:42 AM
- Checked
- Aug 27, 2026, 11:42 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
BTIG Reiterates Buy on Lucid Diagnostics, Maintains $2.5 Price Target
BTIG analyst Mark Massaro reiterates Lucid Diagnostics (NASDAQ:LUCD) with a Buy and maintains $2.5 price target.
Read original at benzingaLucid Diagnostics Q2 2026 Earnings Call: Complete Transcript
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive
Read original at benzinga